Metagenome-wide association of gut microbiome features for schizophreniaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined the fecal microbiome of 90 medication-free schizophrenia patients and 81 controls, looking for microbial features that track with the disease. Shotgun metagenomic data from treatment-naive patients are rare, limiting prior gut-brain axis research.
How was it studied?
The team built a microbial species classifier from the discovery cohort, then tested it in an independent replication cohort of 45 patients and 45 controls. They also transplanted a schizophrenia-enriched bacterium, Streptococcus vestibularis, into mice.
What did they find?
The classifier separated patients from controls with an AUC of 0.896 in the discovery set and 0.765 on replication. Functional differences included short-chain fatty acid synthesis, tryptophan metabolism, and neurotransmitter synthesis and degradation. Mice given Streptococcus vestibularis showed social behavior deficits and altered peripheral neurotransmitter levels.
Why it matters
The findings suggest specific gut bacteria may causally influence schizophrenia-related behavior, not merely correlate with it. This gives concrete leads, including a candidate species and metabolic pathways, for future cohort and animal studies.